Look at Dr Reddy's Lab, Sun Pharma: Prakash Diwan

Prakash Diwan of prakashdiwan.in told CNBC-TV18, "You will probably see a little bit of a rerating from most of the large pharmaceutical players especially the ones which are US focused, thanks to Mr Clinton’s tweet on bringing down costs for the healthcare segment. Then that has brought all those biotech companies down in the US last night. Now, which means that you will have to depend upon generic imports which are cheaper and India definitely stands to gain there. So, anything which is now off patent and which not in the ambit of the US Food and Drug Administration (FDA), the regulators per se will benefit. So, Dr Reddy's Laboratories is the top beneficiary there."He further added, "Glenmark Pharma with a huge pipeline benefitting significantly and to a large extent, it could be Sun Pharmaceutical Industries and Lupin, but the order remains very clearly Dr Reddy's, Glenmark and Sun Pharma, so I would believe today you will see some price action there and which could be sustainable if there is more leg to what likely next US president thinks about this particular sector."